Japanese Patent Grant

Summary by AI BETAClose X

CRISM Therapeutics Corporation has been granted patent number 7800909 by the Japanese Patent Office for its lead product, ChemoSeed, specifically relating to biodegradable chemotherapeutic drug implants containing irinotecan and their use in treating brain tumours like glioblastoma. This patent covers manufacturing processes and therapeutic applications, strengthening the company's intellectual property position in a key market and enhancing its appeal to potential commercial partners. CRISM Therapeutics is preparing for its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma patients, scheduled to commence in Q1 2026.

Disclaimer*

UK 100

Latest directors dealings